<DOC>
	<DOCNO>NCT02000336</DOCNO>
	<brief_summary>Although cortisone widely use treatment patient early rheumatoid arthritis , best dosage know . Therefore compare two standard prednisolon start dosage placebo treatment patient early active rheumatoid arthritis background establish therapy methotrexate . In total 450 patient include study . Two different treatment arm start 10 60 mg prednisolone , one placebo arm . Duration intervention 12 week . In parallel , patient start medication methotrexate , usual dosage 15 mg/week . Primary efficacy endpoint progression radiographic damage one year compare baseline . Safety monitoring perform .</brief_summary>
	<brief_title>Comparison Effectiveness Two Different Dosages Cortisone Compared Placebo Rheumatoid Arthritis</brief_title>
	<detailed_description>BACKGROUND : Although glucocorticoid ( GCs ) widely use treatment patient early rheumatoid arthritis ( RA ) , best dosage GCs , relate , efficacy safety , know . OBJECTIVE : To compare two standard p.o . GC start dosage non-use GCs treatment patient early active RA background establish 'anchor ' therapy methotrexate ( MTX ) . METHODS : Randomised double-blind placebo-controlled trial two treatment arm ( start 10 60 mg p.o . prednisolone ( P ) , taper 5 mg P per day within 8 week ) one placebo arm , arm comprising 150 patient . Duration intervention 12 week . In parallel , patient start medication MTX , usual dosage 15 mg/week . Primary efficacy endpoint progression radiographic damage one year compare baseline . Secondary endpoint : percentage patient remission , change functional capacity etc . Safety monitoring perform . The analysis perform three hierarchical step . First step analysis covariance compare group initial P dosage 60 mg ( V60 ) placebo group ( Pl ) . In case statistical significant result ( α = 0.05 ) , comparison group start 10 mg P ( V10 ) Pl do second step ( α = 0.05 ) . In case superiority V10 versus Pl , third step non-inferiority test V10 versus V60 ( α = 0.025 ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Diagnosis rheumatoid arthritis base expert opinion accord American College Rheumatology ( ACR ) /European League Against Rheumatism ( EULAR ) 2009 criterion ( Hawker 2009 ) disease duration &lt; 3 year active disease : disease activity score ( DAS ) 28 erythrocyte sedimentation rate ( ESR ) ( Prevoo et al 1995 ) &gt; 4 plus ≥ 3 swollen joint Prior treatment diseasemodifying antirheumatic drug ( DMARDs ) ( except hydroxychloroquine sulfasalazine methotrexate last four week screen ) Clinically relevant comorbidity : concurrent liver disease ( ALT &gt; 2 time upper limit normal ) , active hepatitis B C viral infection , renal disease ( creatinine clearance &lt; 30 ml/minute ) , clinically relevant haematological disease due judgement rheumatologist , uncontrolled diabetes mellitus , uncontrolled arterial hypertension , relevant immunodeficiency incl . HIVinfection , clinically significant pulmonary fibrosis , history malignant melanoma , complicate refractory gastrointestinal ulcer , presence history severe infection , uncontrolled increase intraocular pressure , pregnancy plan pregnancy , noncompliance , age &lt; 18 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>radiographic damage</keyword>
	<keyword>rheumatoid arthritis</keyword>
</DOC>